111938-17-1

Basic information

• Product Name: AKOS BB-9420
• Synonyms: AKOS BB-9420;5-IODO-BENZENE-1,3-DIAMINE;1,3-Benzenediamine, 5-iodo-
• CAS NO: 111938-17-1
• Molecular Formula: C₆H₇IN₂
• Molecular Weight: 234.04
• Mol File: 111938-17-1.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AKOS BB-9420(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BB-9420(111938-17-1)
• EPA Substance Registry System: AKOS BB-9420(111938-17-1)

Safety Data

• Hazardous Substances Data: 111938-17-1(Hazardous Substances Data)

Upstream product

• 99-65-0 meta-dinitrobenzene 
• 98-95-3 nitrobenzene 
• 618-87-1 3, 5-dinitroaniline 
• 6276-04-6 3,5-dinitroiodobenzene 

Downstream Products

• 179411-78-0 tert-butyl (3-amino-5-iodophenyl)carbamate 
• 1048676-86-3 C₁₅H₁₆IN₃O 
• 1451958-74-9 1,1'-(5-iodo-1,3-phenylene)diurea 

Relevant articles and documents

Synthesis, Biological Evaluation, and Computational Analysis of Biaryl Side-Chain Analogs of Solithromycin

There is an urgent need for new antibiotics to mitigate the existential threat posed by antibiotic resistance. Within the ketolide class, solithromycin has emerged as one of the most promising candidates for further development. Crystallographic studies of bacterial ribosomes and ribosomal subunits complexed with solithromycin have shed light on the nature of molecular interactions (π-stacking and H-bonding) between from the biaryl side-chain of the drug and key residues in the 50S ribosomal subunit. We have designed and synthesized a library of solithromycin analogs to study their structure-activity relationships (SAR) in tandem with new computational studies. The biological activity of each analog was evaluated in terms of ribosomal affinity (Kd determined by fluorescence polarization), as well as minimum inhibitory concentration assays (MICs). Density functional theory (DFT) studies of a simple binding site model identify key H-bonding interactions that modulate the potency of solithromycin analogs.

MLKL INHIBITORS

Purine derivatives that inhibit cellular necroptosis and/or human MLKL, pharmaceutical compositions thereof, and methods of treating an MLKL-mediated disorder with an effective amount of the compound or composition. Said MLKL-mediated disorder is pathology associated necroptosis, including ischemia-reperfusion damage, neurodegeneration, and inflammatory diseases such as acute pancreatitis, multiple sclerosis, inflammatory bowel disease, and allergic colitis.

Triplex-forming ability of oligonucleotides containing 1-aryl-1,2,3- triazole nucleobases linked via a two atom-length spacer

Phosphoramidites containing 2-propynyloxy or 1-butyn-4-yl as nucleobase precursors were synthesized and introduced into oligonucleotides using an automated DNA synthesizer. Copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition of the oligonucleotides wi